DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Velcade (Bortezomib) - Fatigue - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Fatigue (87)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Velcade (Bortezomib) where reactions include fatigue. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 87   Next >>

Possible Velcade side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27

Patient: male, weighing 93.4 kg (205.5 pounds)

Reactions: Confusional State, Fatigue, Pseudomembranous Colitis, Asthenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade
    Dosage: 2.95 mg, cyclic
    Indication: Multiple Myeloma
    Start date: 2011-02-07
    End date: 2011-03-03

Decadron
    Dosage: unk
    Indication: Multiple Myeloma

Other drugs received by patient: Zofran; Cipro / 00042702 /; Duragesic-100; Armodafinil; Xanax; Morphine Sulfate; Miralax; Valtrex



Possible Velcade side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22

Patient: female

Reactions: Fatigue, Neuropathy Peripheral

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Doxorubicin HCL
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Velcade side effects in female

Reported by a physician from United States on 2012-08-10

Patient: female

Reactions: Fatigue, Pain, Protein Total Increased, Coombs Test Positive, Constipation, Blood Viscosity Increased

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-09

Patient: 50 year old female

Reactions: Fatigue, Injection Site Pain, Constipation

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in 55 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-03

Patient: 55 year old female

Reactions: Thrombosis, Weight Increased, Fatigue, Neuropathy Peripheral, Hypertension

Drug(s) suspected as cause:
Thalidomide

Velcade



Possible Velcade side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: maintenance

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Rituximab
    Dosage: maintenance

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Velcade side effects in 54 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-27

Patient: 54 year old male

Reactions: Neuropathy Peripheral, Fatigue

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in 61 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-26

Patient: 61 year old male

Reactions: Neuropathy Peripheral, Fatigue, Gastrointestinal Disorder, Decreased Appetite

Drug(s) suspected as cause:
Velcade
    Indication: Multiple Myeloma
    Start date: 2009-08-01
    End date: 2010-06-01

Revlimid / Dexamethasone
    Indication: Multiple Myeloma
    Start date: 2009-08-01



Possible Velcade side effects in 62 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18

Patient: 62 year old female

Reactions: Injection Site Erythema, Fatigue, Asthenia, Decreased Appetite

Drug(s) suspected as cause:
Velcade
    Dosage: sq
    Indication: Multiple Myeloma

Revlimid



Possible Velcade side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18

Patient:

Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Velcade
    Dosage: 1.3 milligram/sq. meter
    Indication: Multiple Myeloma

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma

Revlimid
    Dosage: 15 milligram
    Administration route: Oral

Cyclophosphamide
    Dosage: 500 milligram/sq. meter
    Indication: Multiple Myeloma

Velcade
    Dosage: 1.3 milligram/sq. meter

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma



Possible Velcade side effects in female

Reported by a consumer/non-health professional from United States on 2012-07-17

Patient: female

Reactions: Fatigue, Pain, Protein Total Increased, Constipation, Coombs Test Positive, Blood Viscosity Increased

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in

Reported by a consumer/non-health professional from United States on 2012-07-16

Patient:

Reactions: Vomiting, Dyspnoea, Nausea, Pyrexia, Cardiomyopathy, Renal Failure Chronic, Weight Increased, Tumour Lysis Syndrome, Fatigue, Respiratory Failure, Vitamin B12 Deficiency, Alopecia, Ejection Fraction Decreased, Arteriosclerosis Coronary Artery, Respiratory Tract Infection, Cardiac Failure Congestive

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Multiple Myeloma
    Start date: 2007-11-05
    End date: 2007-12-03

Dexamethasone
    Dosage: 20 mg, cyclic
    Indication: Multiple Myeloma

Other drugs received by patient: OS-CAL / 00108001 /; Colace; Nexium; Synthroid; Allopurinol; Lasix; Lisinopril; Lovenox; Aspirin



Possible Velcade side effects in female

Reported by a consumer/non-health professional from United States on 2012-07-16

Patient: female, weighing 59.0 kg (129.7 pounds)

Reactions: Vomiting, Fatigue, Nausea, Oesophagitis, Dehydration, Urinary Tract Infection, Hypotension, Systemic Inflammatory Response Syndrome, Lobar Pneumonia, Renal Failure Acute

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade

Other drugs received by patient: Prilosec; Colace; Prozac; Fentanyl; Potassium Chloride; Vicodin; Iron; Atenolol; Synthroid; Warfarin Sodium



Possible Velcade side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-12

Patient: female

Reactions: Death, Neuropathy Peripheral, Fatigue, Diarrhoea, Colitis Microscopic

Adverse event resulted in: death, disablity

Drug(s) suspected as cause:
Velcade
    Dosage: 2.4 mg, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2009-12-01
    End date: 2010-09-01

Revlimid
    Dosage: 25 mg, qd
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2009-04-01
    End date: 2010-12-01

Revlimid
    Dosage: 25 mg, qd
    Administration route: Oral
    Start date: 2011-01-01
    End date: 2011-03-01

Other drugs received by patient: Aredia; Dexamethasone Sodium Posphate



Possible Velcade side effects in female

Reported by a consumer/non-health professional from United States on 2012-07-06

Patient: female

Reactions: Back Pain, Dyspnoea, Pain in Extremity, Bone Pain, Anxiety, Fatigue, Activities of Daily Living Impaired, Coordination Abnormal, Depression, Asthenia

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in female

Reported by a physician from United States on 2012-07-06

Patient: female, weighing 92.0 kg (202.4 pounds)

Reactions: White Blood Cell Count Decreased, Dyspnoea, Anaemia, Febrile Neutropenia, Muscular Weakness, Acidosis, Renal Failure Chronic, Fatigue, Sepsis, Platelet Count Decreased, Hypoxia, Neutrophil Count Decreased, Lymphocyte Count Decreased, Decreased Appetite

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-02
    End date: 2012-06-06

Decitabine
    Dosage: 20 mg/m2, cyclic
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-02
    End date: 2012-06-08



Possible Velcade side effects in female

Reported by a physician from United States on 2012-07-05

Patient: female

Reactions: Death, Neuropathy Peripheral, Fatigue, Colitis Microscopic

Adverse event resulted in: death, disablity

Drug(s) suspected as cause:
Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Start date: 2011-01-01
    End date: 2011-03-01

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2009-04-01
    End date: 2010-12-01

Velcade
    Dosage: 2.4 milligram
    Start date: 2009-12-01
    End date: 2010-09-01

Other drugs received by patient: Dexamethasone Sodium Phosphate; Aredia



Possible Velcade side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Velcade
    Dosage: on days 1 and 8

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Cyclophosphamide

Velcade
    Dosage: on days 1 and 8
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: maintenance

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: maintenance

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Velcade
    Dosage: on days 1 and 8
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Indication: B-Cell Lymphoma



Possible Velcade side effects in male

Reported by a consumer/non-health professional from United States on 2012-07-05

Patient: male

Reactions: Fatigue, Neuropathy Peripheral, Diarrhoea, Dizziness, Asthenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in 62 year old male

Reported by a physician from United Kingdom on 2012-07-03

Patient: 62 year old male

Reactions: Fatigue, Diarrhoea, Nausea, Pulmonary Embolism, Electrolyte Imbalance, Lower Respiratory Tract Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 160 mg;;po
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2010-01-05
    End date: 2010-02-26

Velcade
    Dosage: 2.5 mg;;iv, 1.3 mg;;iv
    Indication: Multiple Myeloma
    Start date: 2010-03-29
    End date: 2010-03-29

Velcade
    Dosage: 2.5 mg;;iv, 1.3 mg;;iv
    Indication: Multiple Myeloma
    Start date: 2010-01-05

Other drugs received by patient: Acyclovir; Fluconazole; Dexamethasone; Fentanyl; Furosemide; Lansoprazole; Melphalan Hydrochloride; Vincristine; Doxorubicin HCL; Metformin Hydrochloride; Pioglitazone; Cyclophosphamide; Thalidomide; Glimepiride



Possible Velcade side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29

Patient: male, weighing 128.1 kg (281.8 pounds)

Reactions: Musculoskeletal Pain, Anaemia, Mental Status Changes, Multiple Myeloma, Hypercalcaemia, Osteonecrosis, Fatigue, Gait Disturbance, Thrombocytopenia, Pathological Fracture

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Cytoxan

Revlimid
    Indication: Product Used FOR Unknown Indication

Velcade
    Dosage: unk
    Start date: 2012-05-03

Dexamethasone
    Indication: Product Used FOR Unknown Indication

Velcade
    Dosage: 1.3 mg, cyclic
    Indication: Multiple Myeloma
    Start date: 2012-03-07
    End date: 2012-04-23

Etoposide
    Indication: Product Used FOR Unknown Indication

Other drugs received by patient: Metoprolol Succinate; Ramipril; Duloxetime Hydrochloride; Glucophage; Catapres / 00171101 /; Allopurinol; Cymbalta; Percocet; Zometa; Ativan; Ascriptin A / D



Possible Velcade side effects in 62 year old female

Reported by a physician from United States on 2012-06-28

Patient: 62 year old female

Reactions: Fatigue, Pericarditis, Pneumonia Cytomegaloviral

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in female

Reported by a physician from United States on 2012-06-28

Patient: female

Reactions: Fatigue, Pain, Protein Total Increased, Coombs Test Positive, Constipation, Blood Viscosity Increased

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in 28 year old female

Reported by a physician from United States on 2012-06-28

Patient: 28 year old female

Reactions: Vanishing Bile Duct Syndrome, Fatigue, Liver Function Test Abnormal

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-27

Patient:

Reactions: Nausea, Chills, Anaemia, Constipation, Neuropathy Peripheral, Fatigue, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: maintenance

Velcade
    Dosage: on days 1 and 8
    Indication: Chronic Lymphocytic Leukaemia

Velcade
    Dosage: on days 1 and 8
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Velcade
    Dosage: on days 1 and 8

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Doxorubicin HCL
    Dosage: on day 1

Rituximab
    Dosage: on day 1

Cyclophosphamide
    Indication: B-Cell Lymphoma

Cyclophosphamide

Doxorubicin HCL
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma



Possible Velcade side effects in female

Reported by a consumer/non-health professional from United States on 2012-06-22

Patient: female

Reactions: Back Pain, Dyspnoea, Pain in Extremity, Bone Pain, Anxiety, Fatigue, Activities of Daily Living Impaired, Coordination Abnormal, Depression, Asthenia

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in

Reported by a physician from United States on 2012-06-22

Patient:

Reactions: Fatigue, Blood Count Abnormal

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in 72 year old female

Reported by a consumer/non-health professional from United States on 2012-06-21

Patient: 72 year old female, weighing 59.0 kg (129.7 pounds)

Reactions: Vomiting, Fatigue, Nausea, Urinary Tract Infection, Dehydration, Hypotension, Systemic Inflammatory Response Syndrome, Lobar Pneumonia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in female

Reported by a consumer/non-health professional from United States on 2012-06-20

Patient: female, weighing 92.0 kg (202.4 pounds)

Reactions: White Blood Cell Count Decreased, Dyspnoea, Anaemia, Muscular Weakness, Acidosis, Renal Failure Chronic, Fatigue, Sepsis, Platelet Count Decreased, Hypoxia, Neutrophil Count Decreased, Lymphocyte Count Decreased

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Decitabine
    Dosage: 20 mg/m2, cyclic
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-02
    End date: 2012-06-08

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-02
    End date: 2012-06-06



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017